• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Tang Kevin bought $1,806,220 worth of shares (122,416 units at $14.75) (SEC Form 4)

    9/18/24 4:31:08 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $OMIC alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    TANG KEVIN

    (Last) (First) (Middle)
    4747 EXECUTIVE DR
    SUITE 210

    (Street)
    SAN DIEGO CA 92121

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Singular Genomics Systems, Inc. [ OMIC ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    09/16/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 09/16/2024 P 50,416 A $12.74(1) 300,000 I By LP(2)
    Common Stock 09/17/2024 P 40,000 A $15.33(3) 340,000 I By LP(2)
    Common Stock 09/18/2024 P 32,000 A $17.21(4) 372,000 I By LP(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    TANG KEVIN

    (Last) (First) (Middle)
    4747 EXECUTIVE DR
    SUITE 210

    (Street)
    SAN DIEGO CA 92121

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    TANG CAPITAL MANAGEMENT LLC

    (Last) (First) (Middle)
    4747 EXECUTIVE DR
    SUITE 210

    (Street)
    SAN DIEGO CA 92121

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    TANG CAPITAL PARTNERS LP

    (Last) (First) (Middle)
    4747 EXECUTIVE DR
    SUITE 210

    (Street)
    SAN DIEGO CA 92121

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $11.55 to $13.25. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1, 3 and 4 herein.
    2. The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP.
    3. These shares were purchased in multiple transactions ranging from $13.04 to $17.22.
    4. These shares were purchased in multiple transactions ranging from $16.25 to $18.69.
    Kevin Tang 09/18/2024
    Kevin Tang, Manager 09/18/2024
    Kevin Tang, Manager of Tang Capital Management, LLC, General Partner 09/18/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $OMIC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OMIC

    DatePrice TargetRatingAnalyst
    8/17/2022$10.00 → $4.50Buy → Neutral
    UBS
    8/10/2022$3.50Buy → Neutral
    Goldman
    8/10/2022$3.00Buy → Underperform
    BofA Securities
    1/7/2022$21.00Neutral → Buy
    BofA Securities
    10/15/2021Outperform
    Cowen
    More analyst ratings

    $OMIC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Tang Kevin bought $1,806,220 worth of shares (122,416 units at $14.75) (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      9/18/24 4:31:08 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Spaventa Andrew bought $49,612 worth of shares (118,468 units at $0.42) (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      11/20/23 4:31:38 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Glezer Eli N. bought $85,640 worth of shares (200,000 units at $0.43), increasing direct ownership by 5% to 4,570,000 units (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      11/20/23 4:30:55 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OMIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Tang Kevin returned 372,000 shares to the company (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      2/27/25 8:54:47 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Executive Officer Spaventa Andrew returned 143,310 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      2/25/25 8:12:58 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Financial Officer Meeter Dalen returned 9,502 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      2/25/25 8:11:40 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OMIC
    SEC Filings

    See more
    • Singular Genomics Systems Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Material Modification to Rights of Security Holders, Changes in Control of Registrant

      8-K - Singular Genomics Systems, Inc. (0001850906) (Filer)

      2/27/25 1:42:39 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13D/A filed by Singular Genomics Systems Inc.

      SCHEDULE 13D/A - Singular Genomics Systems, Inc. (0001850906) (Subject)

      2/25/25 9:18:06 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form EFFECT filed by Singular Genomics Systems Inc.

      EFFECT - Singular Genomics Systems, Inc. (0001850906) (Filer)

      2/24/25 12:15:05 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OMIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Singular Genomics Systems downgraded by UBS with a new price target

      UBS downgraded Singular Genomics Systems from Buy to Neutral and set a new price target of $4.50 from $10.00 previously

      8/17/22 9:15:00 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics Systems downgraded by Goldman with a new price target

      Goldman downgraded Singular Genomics Systems from Buy to Neutral and set a new price target of $3.50

      8/10/22 6:31:06 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics Systems downgraded by BofA Securities with a new price target

      BofA Securities downgraded Singular Genomics Systems from Buy to Underperform and set a new price target of $3.00

      8/10/22 6:30:40 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials